Celyad SA (CYAD) Hits New 52-Week Low at $20.90
Celyad SA (NASDAQ:CYAD) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $20.90 and last traded at $21.05, with a volume of 10,370 shares. The stock had previously closed at $21.45.
Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Celyad SA from a “hold” rating to a “buy” rating and set a $56.00 target price on the stock in a research note on Wednesday, May 25th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $95.00 target price on shares of Celyad SA in a research note on Tuesday, June 7th.
The stock’s market cap is $187.38 million. The firm’s 50-day moving average is $24.08 and its 200 day moving average is $37.92.
An institutional investor recently raised its position in Celyad SA stock. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Celyad SA (NASDAQ:CYAD) by 24.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,161 shares of the company’s stock after buying an additional 3,426 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.18% of Celyad SA worth $429,000 as of its most recent SEC filing.
Celyad SA Company Profile
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.